Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations

An Arcutis Biotherapeutics executive sold 1,691 shares of common stock to cover tax obligations related to vesting performance-based Restricted Stock Units.

Summary

• Patrick Burnett, an Executive Vice President and Chief Medical Officer at Arcutis Biotherapeutics, sold 1,691 shares of common stock on December 31, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of performance-based Restricted Stock Units (RSUs) granted on August 3, 2020.
• The shares were sold at a weighted average price of $14, with individual transactions ranging from $13.8068 to $14.40.
• Following the transaction, Burnett directly owns 126,978 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use RSUs as part of their compensation packages, leading to similar transactions by executives at other firms.
• The sale price range of $13.8068 to $14.40 is within the typical range for stock sales related to vesting events.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, stock sale, insider trading, Form 4, Patrick Burnett, Restricted Stock Units, tax obligations